Epithelial --mesenchymal transition (EMT) is a developmental program of signaling pathways that determine commitment to epithelial and mesenchymal phenotypes. In the prostate, EMT processes have been implicated in benign prostatic hyperplasia and prostate cancer progression. In a model of Pten-and TP53-null prostate adenocarcinoma that progresses via transforming growth factor b-induced EMT, mesenchymal transformation is characterized by plasticity, leading to various mesenchymal lineages and the production of bone. Here we show that SLUG is a major regulator of mesenchymal differentiation. As microRNAs (miRs) are pleiotropic regulators of differentiation and tumorigenesis, we evaluated miR expression associated with tumorigenesis and EMT. Mir-1 and miR-200 were reduced with progression of prostate adenocarcinoma, and we identify Slug as one of the phylogenetically conserved targets of these miRs. We demonstrate that SLUG is a direct repressor of miR-1 and miR-200 transcription. Thus, SLUG and miR-1/miR-200 act in a self-reinforcing regulatory loop, leading to amplification of EMT. Depletion of Slug inhibited EMT during tumorigenesis, whereas forced expression of miR-1 or miR-200 inhibited both EMT and tumorigenesis in human and mouse model systems. Various miR targets were analyzed, and our findings suggest that miR-1 has roles in regulating EMT and mesenchymal differentiation through Slug and functions in tumor-suppressive programs by regulating additional targets.
INTRODUCTION
Epithelial --mesenchymal transition (EMT) is a developmental regulatory program that mediates plasticity between epithelial and mesenchymal phenotypes in normal and pathological settings. 1 An irreversible EMT program leads to pathological fibrosis. A reversible EMT program that is characterized by a partial EMT phenotype has been implicated as a common mechanism associated with invasion and metastasis. 2 EMT plays an important role in various pathological processes within the prostate, especially prostate cancer progression. Individual invasive prostate cancer cells within high Gleason grade tumors are indicative of EMT. Consistent with this, the analysis of prostate cancer tissue arrays has shown that loss of the epithelial marker, E-cadherin (CDH1), and gain of the mesenchymal marker, N-cadherin (CDH2), is associated with multiple end points of progression and cancer-associated death. 3, 4 In addition, benign prostatic hyperplasia, an enlargement of the prostate characterized by increased stromal and glandular elements, demonstrates evidence of the accumulation of mesenchymal-like cells derived from prostate epithelium. 5 A set of transcription factors, including SNAI1, SNAI2 (SLUG), TWIST and ZEB1/2, were initially identified as regulating epithelial--mesenchymal plasticity in embryonic morphogenesis, and subsequently have been shown to be capable of inducing EMTs on their own when expressed in epithelial cells. 1 During cancer progression, a variety of signaling pathways, originating in the carcinoma cells or the microenvironment, induce EMT. Members of the transforming growth factor b (TGFb) family are principal extracellular inducers of EMT. 6 Although TGFb is recognized as a tumor suppressor in transformation of prostate epithelia, it can also promote invasion and malignant progression of prostate cancer. 7, 8 In late-stage prostate cancer, TGFb expression is elevated in prostate tumors and the circulation, with expression levels negatively correlated with patient prognosis. 9, 10 In addition to EMT transcription factors, microRNAs (miRs) have been shown to be regulators of EMT and cancer cell invasion. The miR-200 family is a prominent group where high and low miR-200 expression levels correlate with epithelial and mesenchymal phenotypes, respectively. 11, 12 Elements of the EMT program including increased EMT transcription factor expression and decreased miR-200 expression are associated with the acquisition of cancer stem cell traits and tumor-initiating capacity. 2,13 --14 We previously have characterized the PB-Cre4Pten fl/fl TP53 fl/fl model of aggressive prostate cancer that demonstrates prostatic intraepithelial neoplasia at 8 weeks, adenocarcinoma formation by 4 months and the progressive development of EMT and sarcomatoid carcinoma, leading to the death of most animals at about 7 months of age. 15 We noted the presence of heterologous chondrosarcomatous and osteosarcomatous elements in some tumors, similar to prostatic sarcomatoid carcinomas that have been described in patients. 16 To investigate the origin of tumor heterogeneity, clonal epithelial cell lines were established from tumors to evaluate the differentiation potential of clonally derived tumor-initiating cells. 15 Upon in vivo inoculation, some luminal epithelial lines underwent progressive sarcomatoid carcinoma formation, formally demonstrating an epithelial-to-mesenchymal transition origin for sarcomatoid carcinomas.
Using the AC3 clonal cell line, which undergoes TGFb-induced EMT in vitro, we previously have shown that depletion of Slug inhibited EMT, whereas depletion of Snail was significantly less rate limiting. 17 Here we have investigated the role of miR families in Slug regulation and determined that a mutually inhibitory feedback circuit exists for miR-1 and miR-200 with Slug. The functional roles of these interacting molecular pathways were evaluated with respect to EMT, mesenchymal differentiation and tumorigenicity.
RESULTS
Pten/TP53 deletion in prostate epithelium leads to adenocarcinoma, which progresses to sarcomatoid carcinoma with mesenchymal stem cell characteristics Our previous observation of bone and cartilage elements in PB-Cre4Pten fl/fl TP53 fl/fl prostate tumors suggested a potentially high degree of EMT-related plasticity. Therefore, we evaluated the range of mesenchymal differentiation markers expressed in prostatic adenocarcinomas and sarcomatoid carcinomas. As shown in Figure 1a , adenocarcinomas characteristically expressed high levels of Cdh1, and sarcomatoid carcinomas expressed reduced levels of Cdh1 and significantly increased levels of Vim. The differentiation markers included general (Fsp1) and lineage-dependent myofibroblasts (a-SMA), adipocyte (Fabp4), osteoblast (Spp1 and Runx2), chondrocyte (Col2a1) and skin fibroblast (Desmin) mesenchymal markers. All mesenchymal markers were highly increased in sarcomatoid carcinoma tumors. Interestingly, adenocarcinomas also expressed, relative to wildtype prostates, elevated levels of Fabp4, Spp1, Runx2 and Col2a1. Thus, it appeared that in vivo EMT involved differentiation plasticity overlapping with the range of differentiated cell types produced by mesenchymal stem cells (MSCs).
To investigate mesenchymal differentiation in a tractable system, we used the clonal AC3 cell line, which is an EpCAM þ , CK8 þ epithelial cell line that undergoes spontaneous TGFb-dependent EMT in vitro. We previously determined that fluorescence-activated cell sorting (FACS)-separated EpCAM þ (E þ ) epithelial cells expressing CK8 produce EpCAM negative (EÀ) mesenchymal-like cells expressing VIM. 17 In addition, we also determined that EMT is dependent on Slug expression, and therefore, we anticipated that Slug-depleted AC3 cells (AC3 þ SKD) would lack MSC-like characteristics. To characterize their in vivo mesenchymal differentiation potential, AC3 cells were injected subcutaneously. The tumors resulting from AC3E þ cells contained a mixture of epithelial and mesenchymal cells, including populations of cells expressing the SLUG EMT marker and the FABP4 adipocyte marker, and 60% of tumors showed evidence of calcified bone-like material (Figures 1b and c) . Thus, epithelial ACE þ cells underwent EMT and heterogeneous mesenchymal differentiation. In tumors initiated from AC3EÀ cells, the proportion of cells expressing SLUG and FABP4 was increased, and there was evidence of bone in all the tumors that were analyzed. The mesenchymal markers were almost completely absent in Slugdepleted AC3 tumors.
To determine their autonomous differentiation potential, AC3 cells were placed in culture media with additives that stimulate MSC differentiation to adipocytes, chondrocytes or osteoblasts, and the cultured cells were subsequently stained with the respective lineage markers FABP4, COL2A1 or SPP1 (osteopontin). As shown in Figure 1d , AC3 cells demonstrated induced, SLUGdependent expression of the three mesenchymal lineages. To evaluate bone formation function, AC3 cells were cultured in osteogenic media with or without bone morphogenetic protein-2. As shown in Figure 1e , induced osteoblast-like cells produced mineralized matrix and were responsive to additional bone morphogenetic protein-2-stimulated differentiation. We conclude that the heterologous elements in prostatic Pten/TP53-null sarcomatoid tumors are consistent with MSC-like plasticity of epithelial tumor cells that have undergone an EMT.
Mesenchymal differentiation is induced by TGFb
To determine whether the expression of mesenchymal lineage markers could be initiated by TGFb, kinetic analyses of TGFbtreated AC3E þ and AC3E þ SKD cells were performed. Adipocyte, osteoblast and to a lesser degree chondrocyte markers increased over time following TGFb incubation of AC3Eþ , but not AC3E þ SKD (Figure 2a ). The specificity of Slug depletion was shown by reconstitution of the TGFb-dependent mesenchymal phenotypes by Slug re-expression (Supplementary Figure S1) . Western blot results were confirmed by immunofluorescent cell staining of TGFb-treated AC3Eþ and AC3Eþ SKD cells (Figure 2b) . Also, when AC3 cultures that had undergone spontaneous EMT over time were separated into E þ and EÀ populations, mesenchymal lineage markers were observed in the EÀ cells (Figure 2c ). Of interest, two fate-determining transcription factors, the stem cell factor SOX2 and the osteoblast/chondrocyte differentiation factor RUNX2, were expressed in TGFb-induced mesenchymal cells.
Slug is regulated through a mutually inhibitory feedforward loop by miR-1 and miR-200b Gene and miR profiles were analyzed to address potential regulatory mechanisms of TGFb-induced Slug increases. MiRs, differentially expressed between normal prostate epithelium and Pten/TP53-null prostate sarcomatoid carcinomas and cell lines (Figure 5d ), establishing that significant SLUG binding occurs at miR-1-1 E2, miR-1-2 E3 and miR-200b E4, E5 and E6. DNA fragments containing individual E-boxes that exist in the pri-miR-1-1, miR-1-2 and miR-200b promoters were cloned into a promoter-RFP reporter. Specificity for the cloned E-box elements was assayed using paired constructs containing point mutations within the E-box sequence element (Figure 5b ). Cotransfection of the E-box reporters and a Slug expression vector strongly suppressed reporter activity for E1, E2, E3, E4 and E6 containing constructs, in a manner that was dependent on an intact E-box sequence (Figure 5e ). These data imply that miR-1-1, miR-1-2 and miR-200b transcription is subject to TGFb-induced SLUG-dependent suppression and mutually repressive regulation exists for miR's 1/200b and Slug. (Figure 8a ). We have shown previously that AC3Eþ and AC3Eþ SKD cells demonstrated tumorigenicity, but had distinct EMT phenotypes. 17 As an additional measure of tumor growth rate, AC3Eþ and AC3Eþ SKD tumor sections were stained for the proliferation marker, Ki-67 (Figure 8b) . The two tumor types demonstrated statistically similar proliferation indices. As shown in Figure 8c , AC3Eþ cells injected subcutaneously formed tumors with mixed epithelial and mesenchymal histologies, while AC3Eþ SKD cells produced well-differentiated adenocarcinomas. By contrast to Slug-depleted cells, AC3Eþ cells expressing lentivirus-encoded miR-1 and/or miR-200b precursors had significantly less tumorigenic potential as demonstrated by delayed tumor formation and slow growth of the resulting tumors (Figure 8a ). The small tumors that did form had a welldifferentiated epithelial morphology and showed decreased levels of Slug and mesenchymal lineage markers relative to control miRtreated cells (Figures 8c and d) . A comparison (Figure 8f ) of miR-1 (Figure 8e) showed that the tumors that eventually arose from pre-miR or Slug-depleted lines expressed significantly lower miR-1 and miR200b levels than the injected cell lines. This suggests that selection for low miR levels associated with tumor growth had occurred (Figures 8d and e) . These data imply that miR-1 and miR-200 have tumor suppressor activity.
MiR-1 regulates EMT and mesenchymal commitment via Slug and appears to independently act as a tumor suppressor by regulating additional targets We asked whether the suppression of Slug by miR-1 and miR-200 was the main determinant that inhibited mesenchymal commitment. We engineered SLUG expression in miR-1-and miR-200b-overexpressing cells using a Slug DNA construct missing the 3 0 -UTR. In these cells, we observed significant expression of mesenchymal lineage markers (Figure 9a ), implying that Slug expression is sufficient for mesenchymal commitment, and therefore is the major miR-1 or miR-200 target responsible for the mesenchymal differentiation phenotype. Conversely, the accelerated tumor formation by Slug-depleted cells compared with miR-1-or miR200b-expressing cells suggest that miR-1 and miR-200 inhibit expression of targets that function to promote tumorigenesis independent of Slug and mesenchymal commitment. To validate the presence of Slug-independent miR targets, we focused upon miR-1 and assayed a number of predicted miR-1 targets listed in Figure 9b . As shown in Figure 9c , these targets are induced by miR-1 depletion in the absence of Slug as assayed in anti-miR-1-infected AC3Eþ SKD cells. In contrast to the mesenchymal lineage markers shown in Figure 9a , Bndf, Spnb2, 14-3-3t and Kif2a were minimally effected or unaffected by Slug overexpression in cells with forced expression of miR-1. Interestingly, Ets1 and Gja1 appeared to have both Slug-dependent and -independent components in their regulation. Taken together, it appears that miR-1 regulates EMT and mesenchymal commitment via Slug and acts independently as a tumor suppressor by regulating additional targets.
DISCUSSION
We describe here a model of progressive prostate cancer that demonstrates TGFb-dependent EMT and associated plasticity leading to variable mesenchymal differentiation. SLUG depletion prevents the subsequent induction of Snail and Zeb1/2 and inhibits EMT in this model. 17 We Consistent with this, EMT of the AC3 cell line showed plasticity of mesenchymal differentiation, demonstrating inducible adipocyte, chondrocyte and osteocyte lineage markers. Sarcomatoid carcinoma of the prostate in humans is a rare cancer, which usually is diagnosed following hormonal or radiation treatment of prostate adenocarcinoma. 16 The human tumors share many histological characteristics with the mouse tumors described here, with 30% of human cases containing heterologous elements such as chondrosarcomas and osteosarcomas. 16 The mesenchymal differentiation observed in AC3 cells is consistent with the proposed role for Slug in normal MSCs. Increasing Slug expression is functionally associated with chondrocyte hypertrophy and osteoblast differentiation. 19 --20 In addition, TP53 has been demonstrated to control the proliferation and differentiation of MSCs. 21 Because loss of TP53 leads to elevated SLUG expression, 22 --23 it is reasonable to suggest that TP53 deletion, increased Slug and mesenchymal differentiation plasticity are mechanistically linked.
We have shown previously that depletion of Slug in AC3 cells led to an MET in vitro and in vivo, consistent with the required role for Slug in EMT. 17 Slug-depleted AC3 cells retained tumorigenicity, similar to the recently described tumorigenic MET in a human breast cancer model. 24 In AC3 cells, miR-200 or miR-1 overexpression led to an MET, but in contrast to Slug depletion, also delayed tumor development. We have shown that miR-200 and miR-1 suppression of Slug expression was predominantly responsible for MET. Slug reconstitution of miR-1-and miR-200-expressing cells led to their morphological transformation and expression of EMT (vimentin) and various mesenchymal differentiation markers. These data suggest that Slug expression is sufficient to induce EMT in this system, and that the loss of mesenchymal markers following miR-200 and miR-1 expression is indirect and secondary to loss of Slug.
Taken together, one reasonable interpretation of these data is that there are Slug-independent miR-1 and miR-200 target genes that are required for tumorigenesis, although other possibilities exist. In support of prostate cancer tumorigenesis being associated with decreased miR-1 levels, miR-1-2 has been found to be differentially downregulated in prostate cancer clinical cases relative to normal prostate, 25 and PC3 cells were inhibited in their growth rate by miR-1 expression (Figure 7e) . Downregulation of miR-1 is not unique to prostate cancer and has been described in a number of cancers, including lung, hepatocellular and colorectal cancers. 26 --28 MET, FOXP1 and HDAC4 among others have been proposed as relevant targets, but the constellation of targets that regulate tumorigenicity has yet to be determined. Of the miR-1 targets shown in Figures 9b and c , miR-1-mediated decreased expression of Kif2a can be anticipated to be growth inhibitory. KIF2A is a microtubule depolymerase that plays a non-redundant role in bipolar spindle formation. RNA interference-mediated loss of Kif2a results in the inhibition of cell cycle progression. 29 We have shown evidence for direct miR-1 targets that are either not influenced by Slug expression (for example, Bndf, Kif2a) or positively influence by Slug expression (for example, Ets1, Gja1). The latter category may be synergistically affected by the regulatory loop of miR-1 depletion and Slug overexpression.
In conclusion, we have shown that Slug is a central regulator of TGFb-initiated prostatic EMT and mesenchymal differentiation associated with sarcomatoid carcinoma formation. miR-1/miR-200 and Slug exist in a mutually inhibitory regulatory loop, resulting in decreased miR-1 and miR-200 associated with EMT. In addition, miR-1 and miR-200 regulate Slug-independent targets whose functions are required for tumorigenesis. Thus, miR-1, miR-200 and Slug compose a regulatory network, whose balance is anticipated to effect prostatic tumorigenesis and progression.
MATERIALS AND METHODS Reagents
PrEGM with supplements was from Lonza (Walkersville, MD, USA); BD Matrigel was from BD Biosciences (San Jose, CA, USA); TGFb1 was from R&D Systems (Minneapolis, MN, USA); and TGFbR1 inhibitor (SB431542) was from Sigma (St Louis, MO, USA). Mir inhibitors (control, mmu-miR-1 and mmu-miR-200b) were from GeneCopoeia (Rockville, MD, USA). All inhibitor sequences are listed in Supplementary Materials (Supplementary  Table S1 ). Primers used to construct wild type and mutant reporters are listed in Supplementary Table S2 . Human SNAI2 short interfering RNA (siRNA) (5 0 -ACAGCGAACUGGACACACA-3 0 ) was from Thermo Scientific (Lafayette, CO, USA).
Cell culture AC3 clonal cell lines were isolated, characterized and maintained as described.
17 PC3 cell lines were from ATCC and cultured in RPMI 1640 media supplemented with 10% fetal calf serum. Transient transfections with PC3 cells were carried out using Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA).
FACS and sorting
FACS staining and analysis were as described previously. Promoter functional analysis using FACS and relative median fluorescent intensity value was measured as described. Table S3 ). For mesenchymal differentiation markers, staining was performed using the Mouse Mesenchymal Stem Cell Functional Identification Kit (R&D Systems). Cells were cultured in 24-well plates or 8-well chamber slides (Nunc, New York, NY, USA) with a-MEM or Dulbecco's modified Eagle's medium/F12 basal medium with adipogenic, osteogenic or chondrogenic supplements for 21 days, and subsequently fixed and stained as described. 15, 31 Immunohistochemistry was performed using the antibodies and antigen retrieval methods indicated in Supplementary Materials (Supplementary Table S4 ). Staining was as described. 15, 31 Real-Time reverse transcription--PCR Total RNA was isolated using mirVana PARIS RNA isolation system (Ambion, Austin, TX, USA). Reverse transcription of cDNA and PCR were performed as described. 15, 31 All reactions were normalized to mouse Gapdh and run in triplicate using primers listed in Supplementary Materials (Supplementary  Table S5 ). MiR reverse transcription and PCR reactions were performed using TaqMan MicroRNA Assays kit (Applied Biosystems, Foster City, CA, USA). All values were normalized to mouse snoRNA202 or human RUX48 endogenous control and run in triplicate (Applied Biosystems).
Western blot analysis
Western blots were carried out as described. 15, 31 Primary antibodies were incubated overnight at 4 1C using the dilutions listed in Supplementary Materials (Supplementary Table S6 ).
In vitro bone formation assay
For in vitro osteogenesis, AC3Eþ SKD or AC3Eþ cells were cultured in 24-well plates with osteoblast-inducing medium containing 10% fetal bovine serum, 5 mM b-glycerophosphate and 100 mg/ml ascorbic acid in the presence or absence of 40 mg/ml bone morphogenetic protein-2. After culturing cells for 21 days, cells were fixed and evaluated using von Kossa staining.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed using the EZ magna ChIP A kit (Millipore, Temecula, CA, USA) with a modified protocol as described in Supplementary Experimental Procedures. Quantitative PCR (QPCR) was performed in triplicate with 2 ml of eluted chromatin. ChIP antibodies and PCR primers are listed in Supplementary Materials (Supplementary Table S7 ). Predictions for transcription factor binding sites within promoter regions were adopted from the AliBaba 2.1 program (http://www.gene-regulation.com/pub/programs.html).
MiR luciferase assay
MiR luciferase assays were performed as described in Supplementary Materials. Predictions for miR binding sites on the Slug 3 0 -UTR were made using the Computational Biology Center, Memorial Sloan Kettering Cancer Center website (www.microRNA.org).
Invasion assay
Invasion assays were carried out as described previously using 1 Â 10 6 cells and RPMI 1640 media supplemented with 10% fetal calf serum in both chambers. 32 
In vitro growth curves
In vitro growth curves were performed as described previously using a density of 2 Â 10 3 cells per well. 33 
Tumorigenicity assays
Tumorigenicity assays were performed as previously described using 1 Â 10 6 tumor cells in 50% Matrigel (Falcon, Hillsborough, NJ, USA). 33 Tumors were radiographed ex vivo using an MX-20 Faxitron X-ray system (Faxitron XRay Corp., Lincolnshire, IL, USA).
Gene microarrays (miRNA and mRNA)
Methods to obtain and process array data were essentially as described. 34 miR-mRNA-negative correlation and enrichment analysis are described in ref.
, 34 except that a P-value of correlation p0.05 was used.
Statistical analysis
Statistical calculations were performed with GraphPad Prism analysis tools. Differences between individual groups were analyzed by one-or two-way analysis of variance test. Bonferroni's post-test was used for comparisons among three or more groups.
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